EDX Medical Group, a provider of digital diagnostic products and services, has announced the launch of a new advanced test for early detection of testicular cancer in the UK.
Known as TC100, this test is non-invasive and is claimed to offer high accuracy in identifying cancer across various ages and ethnic groups. It is said to be particularly effective in detecting cancer recurrences, providing 100% sensitivity during post-treatment monitoring for testicular cancer survivors.
According to EDX Medical, approximately 2,500 new cases of testicular cancer are diagnosed annually in the UK, with around 50,000 survivors potentially benefiting from improved monitoring.
Testicular Cancer Awareness Month in April sees numerous charities and advocacy groups emphasising the importance of early detection. Early diagnosis and treatment can result in survival rates exceeding 90%, said EDX Medical.
EDX Medical Group founder Chris Evans said: “Testicular cancer is a nightmarish thought for young men and there has been a lack of awareness over what to do and an unwillingness to get tested.
“We are delighted to launch in the UK now the best test ever made.
“Given that this disease affects boys from 15 years old to men in their early forties, there are many who could benefit from testing in terms of reassurance and this particularly applies to people who have been diagnosed and need checked on a regular basis.”
The TC100 test requires a blood sample to be collected by a healthcare professional and sent to EDX Medical for analysis.
The process involves examining specific tumour biomarkers and utilising an artificial intelligence (AI)-powered algorithm to generate a detailed report for clinicians, aiding in diagnosis and treatment decisions.
Clinical studies have validated the accuracy and usefulness of the TC100 test in diagnosing primary cases, early detection, metastatic disease, and recurrences of both seminoma and non-seminoma types of testicular cancer.
The assay employs a combination of M371 micro-RNA biomarker analysis with traditional serum biomarkers AFP, HCG, and LDH through a proprietary algorithm.
The TC100 test aligns with NHS protocols by reporting on three tumour biomarkers used in current treatment pathways. It demonstrates up to 99% sensitivity and 96% specificity in initial diagnoses and achieves 100% sensitivity when monitoring for recurrence.
